The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1–methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine) and structurally related compounds
- 1 October 1986
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 6 (4), 389-429
- https://doi.org/10.1002/med.2610060402
Abstract
No abstract availableKeywords
This publication has 108 references indexed in Scilit:
- V. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)Life Sciences, 1985
- IV. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effectsLife Sciences, 1985
- III. Primate model of parkinsonism: Selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeysLife Sciences, 1985
- II. Selective accumulation of MPP+ in the substantia nigra: A key to neurotoxicity?Life Sciences, 1985
- I. MPTP neurotoxicity: An overview and characterization of phases of toxicityLife Sciences, 1985
- Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (NMPTP) in mouse brainJournal of Neural Transmission, 1984
- Recent physiological and pathophysiological aspects of Parkinsonian movement disordersLife Sciences, 1984
- Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian speciesLife Sciences, 1984
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidaseBiochemical and Biophysical Research Communications, 1984
- THE TOTAL SYNTHESIS OF RESERPINEJournal of the American Chemical Society, 1956